{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:45Z","timestamp":1791389025447,"version":"4.3.3"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.ctrv.2007.01.004","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T07:17:53Z","timestamp":1175152673000},"page":"315-324","source":"Crossref","is-referenced-by-count":110,"title":["Chemotherapy of advanced gastric cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"Fernando","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Eugenia","family":"Vega-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta F.","family":"L\u00f3pez-Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctrv.2007.01.004_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdg305","article-title":"European Code against cancer and scientific justification: third version (2003)","volume":"14","author":"Boyle","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2007.01.004_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","article-title":"Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer","volume":"71","author":"Pyrhonen","year":"1995","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.01.004_bib4","unstructured":"Schethauer W, Kornek G, Zeh B. Palliative chemotherapy vs supportive care in patients with metastatic gastric cancer: a randomized trial. In: Second international Conference on biology, prevention and treatment of gastrointestinal malignancies. K\u00f6ln; 1995. p. 65."},{"issue":"2","key":"10.1016\/j.ctrv.2007.01.004_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","article-title":"Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer","volume":"8","author":"Glimelius","year":"1997","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2007.01.004_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1991.9.5.827","article-title":"Sequential high-dose methotrexate and fluorouracil combined with doxorubicin \u2013 a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group","volume":"9","author":"Wils","year":"1991","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib8","unstructured":"Massuti B, Cervantes A, Aranda E, Ant\u00f3n A, Abad A, Rivera F et al. A phase III multicenter randomized trial in advanced gastric cancer: Fluorouracil+leucovorin+epirubicin+cisplatin (FLEP) vs Fluorouracilo+adriamycin+methotrexate+leucovorin (FAMTX): response and survival. In: Sixth International Congress on Anti-Cancer Treatment, Paris; 1996."},{"issue":"13","key":"10.1016\/j.ctrv.2007.01.004_bib9","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0959-8049(98)00262-7","article-title":"Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)","volume":"34","author":"Roth","year":"1998","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2007.01.004_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdg329","article-title":"Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma","volume":"14","author":"Cocconi","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","article-title":"Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2007.01.004_bib12","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","article-title":"Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2007.01.004_bib13","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5","article-title":"A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer","volume":"71","author":"Kim","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2007.01.004_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.1992.10.4.541","article-title":"FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer","volume":"10","author":"Kelsen","year":"1992","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2007.01.004_bib15","first-page":"397","article-title":"The treatment of advanced gastric cancer","volume":"23","author":"Wils","year":"1996","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2007.01.004_bib16","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2007.01.004_bib17","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2007.01.004_bib18","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.bjc.6601802","article-title":"Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists","volume":"90","author":"Wood","year":"2004","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.ctrv.2007.01.004_bib19","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","article-title":"Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma","volume":"23","author":"Ajani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib20","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V 325 Study Group","volume":"24","author":"Van Custem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4045","article-title":"Docetaxel-cisplatin (DC) versus 5-fluorouracil\u2013leucovorin\u2013cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary safety results of a Phase III study","author":"Fahlke","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib22","article-title":"Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin\u2013cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"22","author":"Roth","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2007.01.004_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/sj.bjc.6601724","article-title":"A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer","volume":"90","author":"Park","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.01.004_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.02.163","article-title":"Capecitabine and Docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study","author":"Thuss-Patience","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4207","article-title":"Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC)","author":"Catalano","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib26","article-title":"A phase I\/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer","volume":"22","author":"Kang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4218","article-title":"Phase I\/II study of docetaxel, CDDP and S-1 in unresectable advanced gastric cancer","author":"Takayama","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3b","key":"10.1016\/j.ctrv.2007.01.004_bib28","first-page":"1843","article-title":"Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer","volume":"24","author":"Yoshida","year":"2004","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.bjc.6601891","article-title":"Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer","volume":"91","author":"Lee","year":"2004","journal-title":"Br J Cancer"},{"issue":"2\u20133","key":"10.1016\/j.ctrv.2007.01.004_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/IJGC:32:2-3:115","article-title":"A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia","volume":"32","author":"Jatoi","year":"2002","journal-title":"Int J Gastrointest Cancer"},{"issue":"5b","key":"10.1016\/j.ctrv.2007.01.004_bib31","first-page":"4219","article-title":"Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.)","volume":"23","author":"Giuliani","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2007.01.004_bib32","article-title":"Phase II study of Docetaxel as second line chemotherapy (CT) in metastatic gastric cancer","author":"Vanhoefer","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4188","article-title":"Docetaxel and oxaliplatin combination as second line treatment in patients with advanced gastric cancer","author":"Schinzari","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib34","doi-asserted-by":"crossref","unstructured":"Evans D, Miner T, Ng T, Akerman P, Harrington D, Martel D, Maia C, Cioffi W, Benton D, Safran H. A phase I\/II study of oxaliplatin, docetaxel, and capecitabine in advanced carcinoma of the oesophagus and stomach. 2006 Gastrointestinal Cancer Symposium [Abstr 67].","DOI":"10.1200\/jco.2006.24.18_suppl.14046"},{"issue":"21","key":"10.1016\/j.ctrv.2007.01.004_bib35","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","article-title":"Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study \u2013 FFCD 9803","volume":"22","author":"Bouche","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib36","first-page":"258","article-title":"Safety and efficacy of CPT11\/FA\/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"22","author":"Moehler","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2007.01.004_bib37","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/annonc\/mdg727","article-title":"Irinotecan in the treatment of gastric cancer","volume":"14","author":"Bugat","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4003","article-title":"Randomized phase 3 trial of irinotecan (CPT-11)+5FU\/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients","author":"Dank","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4043","article-title":"Phase I trial of cisplatin (CDDP), docetaxel (TXT) and CPT-11 in patients (p) with advanced esophagogastric cancer: Feasibility and activity related to XPD and UGT1A1 gene polymorphisms","author":"Font","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib40","article-title":"Phase II study of irinotecan+5FU\/FA for patients with previously treated advanced gastric cancer","volume":"22","author":"Peeters","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4079","article-title":"Fractional weekly administration of irinotecan and cisplatin as a second-line treatment for advanced gastric cancer","author":"Jeung","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4072","article-title":"Phase II study of biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer","author":"Baek","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4170","article-title":"Phase II trial evaluating capecitabine and irinotecan (CapeIri) in patients (pts) with esophago\u2013gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy","author":"Assersohn","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib44","unstructured":"Cunningham D, Rao S, Starling N, Iveson T, Nicolson M et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: The RE\u00b7AL-2 Trial. Proceedings of ASCO-06 [Abstr 4017]."},{"key":"10.1016\/j.ctrv.2007.01.004_bib45","unstructured":"Al-Batran SE, Hartmann JT, Probst S et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). Proceedings of ASCO-06 [Abstr 4016]."},{"issue":"23","key":"10.1016\/j.ctrv.2007.01.004_bib46","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1200\/JCO.2002.02.021","article-title":"Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2007.01.004_bib47","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.2004.07.042","article-title":"Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer","volume":"22","author":"Al-Batran","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib48","article-title":"Phase II study of oxaliplatin, 5-fluoruracil and folinic acid in recurrent or metastatic gastric cancer","author":"Bang","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib49","article-title":"Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A\/MGC)","volume":"22","author":"Cavanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4016","article-title":"Oxaliplatin plus 5FU\/Folinic acid (FUFOX Regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial","author":"Duyster","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib51","article-title":"Oxaliplatin in combination with LV5FU2 in Chinese patients with advanced gastric cancer","author":"Jin","year":"2002","journal-title":"Proc Onkologie"},{"key":"10.1016\/j.ctrv.2007.01.004_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4199","article-title":"Oxaliplatin and capecitabine combination chemotherapy for patients with advanced gastric carcinoma: a pilot study results","author":"Park","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4059","article-title":"Oxaliplatin and Capecitabine in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia: A Phase II Study from the North Central Cancer Treatment Group","author":"Jatoi","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib54","article-title":"Lack of resistance to oxaliplatin-based chemotherapy in patients with advanced gastric cancer previously treated with cisplatin-containing regimens: preliminary results of a phase II trial","author":"Catalano","year":"2002","journal-title":"Proc Onkologie"},{"issue":"3","key":"10.1016\/j.ctrv.2007.01.004_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/annonc\/mdg106","article-title":"Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer","volume":"14","author":"Kim","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2007.01.004_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s101200200015","article-title":"Paclitaxel Gastric Cancer Study Group in Japan. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer","volume":"5","author":"Yamaguchi","year":"2002","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2007.01.004_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/annonc\/mdg078","article-title":"Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer","volume":"14","author":"Kruijtzer","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00000421-200302000-00008","article-title":"Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer","volume":"26","author":"Gadgeel","year":"2003","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2007.01.004_bib59","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.bjc.6600345","article-title":"Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and\/or erythropoietin in patients with advanced gastric cancer","volume":"86","author":"Kornek","year":"2002","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2007.01.004_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00001813-200206000-00008","article-title":"Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer","volume":"13","author":"Honecker","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.ctrv.2007.01.004_bib61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1054\/bjoc.2000.1295","article-title":"A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer","volume":"83","author":"Kollmannsberger","year":"2000","journal-title":"Br J Cancer"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib62","article-title":"A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy","volume":"22","author":"Kang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib63","doi-asserted-by":"crossref","DOI":"10.1090\/S0002-9939-05-07831-7","article-title":"Randomized phase II trial of taxanes plus 5-fluorouracil for advanced gastric cancer","author":"Park","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2007.01.004_bib64","first-page":"89","article-title":"Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study","volume":"9","author":"Stathopoulos","year":"2002","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2007.01.004_bib65","article-title":"Phase II study of low-dose Paclitaxel and cisplatin as second-line therapy in 5-Fluorouracil and platinum pretreated gastric cancer","author":"Lee","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2007.01.004_bib66","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/annonc\/mdh343","article-title":"A phase II trial of capecitabine in previously untreated patients with advanced and\/or metastatic gastric cancer","volume":"15","author":"Hong","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2007.01.004_bib67","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/annonc\/mdf323","article-title":"Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer","volume":"13","author":"Kim","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib68","doi-asserted-by":"crossref","unstructured":"Thuss-Patience PC, Kretzschmar A, Loew A, Massenkeil G, Pink D, Lebedinzew B et al. Capecitabine and Docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study. In: Proceedings of ASCO 2005 # 4224; Catalano G, Orditura M, Diadema M, Aurilio G, Ciardiello F, de Vita F. Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC). Proc Am Soc Clin Oncol 2005. [Abstr 4207].","DOI":"10.1200\/jco.2005.23.16_suppl.4224"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib69","article-title":"Epirubicin (E), cisplatin (C) and capecitabine (X) in first-line chemotherapy for patients with advanced gastric cancer","volume":"22","author":"Cho","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib70","doi-asserted-by":"crossref","unstructured":"Kang Y, Kang W, Shin B, Chen J, Xiong J et al. Capecitabine\/cisplatin (XP) vs. continuous infusion of 5-FU\/cisplatin (FP) as first line therapy in patients with advanced gastric cancer (AGC): efficacy and safety results. Proc ASCO-06 [Abst 4018].","DOI":"10.1016\/S1359-6349(07)71004-2"},{"key":"10.1016\/j.ctrv.2007.01.004_bib71","first-page":"356","article-title":"A phase I study of S-1 and weekly CPT-11 for patients with advanced gastric cancer","volume":"22","author":"Yamashita","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2007.01.004_bib72","first-page":"1575","article-title":"A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer","volume":"29","author":"Iwase","year":"2002","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ctrv.2007.01.004_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4055","article-title":"A Phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer","author":"Iwase","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.01.004_bib74","article-title":"Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC)","volume":"22","author":"Ajani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib75","article-title":"Multi-Center Phase II Study of S-1 plus cisplatin in Patients with Advanced Gastric Carcinoma (AGC)","author":"Ajani","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2007.01.004_bib76","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0959-8049(01)00187-3","article-title":"EORTC-ECSG. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)\/European Organization for Research Treatment of Cancer (EORTC) phase II trial","volume":"37","author":"Ravaud","year":"2001","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2007.01.004_bib77","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/1097-0142(20010615)91:12<2288::AID-CNCR1260>3.0.CO;2-8","article-title":"Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma","volume":"91","author":"Jeen","year":"2001","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2007.01.004_bib78","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3748\/wjg.v12.i21.3297","article-title":"Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy","volume":"12","author":"Becker","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"33","key":"10.1016\/j.ctrv.2007.01.004_bib79","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1200\/JCO.2006.08.0887","article-title":"Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"24","author":"Shah","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.ctrv.2007.01.004_bib80","first-page":"ix310","article-title":"Phase II study of Bevacizumab and docetaxel (AVATAX) in metastatic esophageal and gastric cancer","volume":"17","author":"Enzinger","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib81","article-title":"Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)","volume":"Dec 12","author":"Pinto","year":"2006","journal-title":"Ann Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.ctrv.2007.01.004_bib82","first-page":"ix309","article-title":"Cetuximab plus weekly oxaliplatin\/5FU\/FA (FUFOX) in 1st line advanced gastric cancer. First results from a multicenter phase II study of the AIO Upper GI Study Group","volume":"17","author":"Lordick","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib83","unstructured":"Stein A, Al-Batran SE, Arnold D, Peinert S, Siewczynski R, Schmoll HJ. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proceedings of ASCO-GI-2007 [Abstr 47]."},{"key":"10.1016\/j.ctrv.2007.01.004_bib84","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.4054","article-title":"Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer","author":"Adelstein","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.01.004_bib85","unstructured":"Dragovich T, McCoy S, Urba SG, Zanner KS, Fenoglio-Preiser CM, Blanke CD, Abbruzzese JL. Southwest Oncology Group. SWOG 0127: Phase II trial of erlotinib in GEJ and gastric adenocarcinomas. Proc Gastrointestinal Am Soc Clin Oncol Symposium 2005; 107 [Abstr 49]."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:00:48Z","timestamp":1683770448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0305737207000266"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.01.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}